The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
European Globalisation Fund (EGF)
Year: 2011, Case number: 15
8,000 jobs Number of planned job losses
Announcement Date
28 January 2010
Employment effect (start)
1 February 2010
Foreseen end date
31 January 2014
Description
AstraZeneca has announced plans to reduce its worforce by 8000 over the next four years. The company announced that the job cuts will be made across all regions and divisions. It did not detail the precise effects for units, divisions and countries, apart from stressing that its research & development division will be consolidated. The restructuring might affect 3500 jobs in the research & development division of AstraZeneca, leading to a net job loss in the division of 1800 jobs.
Sources
Citation
Eurofound (2010), astrazeneca, Internal restructuring in World, factsheet number 71706, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/71706.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
